Clinical Trials Browser

OTHER × Interventional × lonafarnib × Clear all

NCT00102648 2024-10-17

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

Phase 1 Active not recruiting

34 enrolled

CNSSarcoma

Glioblastoma, Supratentorial Neoplasms, Gliosarcoma

NCT00102635 2018-11-15

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1 Terminated

1 enrolled

Head & Neck

Head and Neck Neoplasms

NCT00005030 2018-11-14

SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver

Phase 1 Withdrawn

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00047502 2018-11-07

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

Phase 1 Completed

23 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00038584 2018-10-30

A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer

Phase 1 Completed

37 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT00038597 2018-10-30

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

Phase 2 Completed

13 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00773474 2016-02-18

Lonafarnib in Metastatic Breast Cancer

Phase 2 Terminated

29 enrolled 11 charts

Breast

Breast Neoplasms

NCT00288444 2012-12-18

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

Phase 1 Terminated

38 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00281515 2012-06-29

Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer

Phase 2 Completed

105 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial